Literature DB >> 9801430

Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres.

M Igartua1, R M Hernández, A Esquisabel, A R Gascón, M B Calvo, J L Pedraz.   

Abstract

PLGA microspheres containing bovine serum albumin (BSA) as a model antigen, were prepared by a double emulsion/solvent extraction method and their in vitro characterization was performed. The same microspheres were used in a series of in vivo studies to evaluate the immune response induced after subcutaneous or oral inoculation following different immunization protocols. The in vivo data confirm that the immunogenicity of the albumin is not affected by the encapsulation procedure. The subcutaneous administration of microspheres showed an immune response (serum IgG levels by ELISA) statistically above BSA solution, even when the dose administered was 10 times lower. The adjuvanticity of the microspheres was found to be comparable to that of Freund's complete adjuvant (FCA), but in contrast to FCA they are biocompatible and did not induce any adverse reaction at the site of injection. A single oral administration of the microspheres was not a successful strategy for the induction of a reproducible response. Therefore, microspheres of 1 and 5 micrometer were orally administered on 3 consecutive days and the response obtained showed that the use of a boosting dose was not necessary for the 1 micrometer particles. These results suggest the possibility of simplifying the immunization schedule to a primary immunization if 1 micrometer particles are administered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801430     DOI: 10.1016/s0168-3659(98)00077-7

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  18 in total

1.  Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.

Authors:  Rajesh Kumar; Grace Ledet; Richard Graves; Dibyadyuti Datta; Shana Robinson; Geetha P Bansal; Tarun Mandal; Nirbhay Kumar
Journal:  Pharm Res       Date:  2015-06-26       Impact factor: 4.200

Review 2.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

3.  From allergen to oral vaccine carrier: A new face of ragweed pollen.

Authors:  Md Jasim Uddin; Harvinder Singh Gill
Journal:  Int J Pharm       Date:  2018-05-03       Impact factor: 5.875

4.  Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery.

Authors:  Thejani E Rajapaksa; Mary Stover-Hamer; Xiomara Fernandez; Holly A Eckelhoefer; David D Lo
Journal:  J Control Release       Date:  2009-11-05       Impact factor: 9.776

Review 5.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

6.  Active self-healing encapsulation of vaccine antigens in PLGA microspheres.

Authors:  Kashappa-Goud H Desai; Steven P Schwendeman
Journal:  J Control Release       Date:  2012-10-24       Impact factor: 9.776

Review 7.  Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  Hum Vaccin Immunother       Date:  2013-08-26       Impact factor: 3.452

Review 8.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

Review 9.  Nanoparticulate adjuvants and delivery systems for allergen immunotherapy.

Authors:  Juliana De Souza Rebouças; Irene Esparza; Marta Ferrer; María Luisa Sanz; Juan Manuel Irache; Carlos Gamazo
Journal:  J Biomed Biotechnol       Date:  2012-02-26

10.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.